Normalization of γ-glutamyl transferase levels is associated with better metabolic control in individuals with nonalcoholic fatty liver disease

被引:11
|
作者
Ma, Qianqian [1 ]
Liao, Xianhua [1 ]
Shao, Congxiang [1 ]
Lin, Yansong [1 ]
Wu, Tingfeng [1 ]
Sun, Yanhong [2 ]
Feng, Shi-Ting [3 ]
Ye, Junzhao [1 ]
Zhong, Bihui [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol, 58 Zhongshan 2 Rd, Guangzhou 510080, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Clin Labs, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Radiol, Guangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Gamma glutamyl transferase; Nonalcoholic fatty liver disease; Liver function; Metabolic syndrome; INSULIN-RESISTANCE; HEPATIC STEATOSIS; AMINOTRANSFERASE; ENZYMES; BIOPSY; INDEX; MEN;
D O I
10.1186/s12876-021-01790-w
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background The normalization of liver biochemical parameters usually reflects the histological response to treatment for nonalcoholic fatty liver disease (NAFLD). Researchers have not clearly determined whether different liver enzymes exhibit various metabolic changes during the follow-up period in patients with NAFLD. Methods We performed a retrospective analysis of patients with NAFLD who were receiving therapy from January 2011 to December 2019. Metabolism indexes, including glucose levels, lipid profiles, uric acid levels and liver biochemical parameters, were measured. Magnetic resonance imaging-based proton density fat fraction (MRI-PDFF) and liver ultrasound were used to evaluate steatosis. All patients received recommendations for lifestyle modifications and guideline-recommended pharmacological treatments with indications for drug therapy for metabolic abnormalities. Results Overall, 1048 patients with NAFLD were included and received lifestyle modification recommendations and pharmaceutical interventions, including 637 (60.7%) patients with abnormal GGT levels and 767 (73.2%) patients with abnormal ALT levels. Patients with concurrent ALT and GGT abnormalities presented higher levels of metabolism indexes and higher liver fat content than those in patients with single or no abnormalities. After 12 months of follow-up, the cumulative normalization rate of GGT was considerably lower than that of ALT (38% vs. 62%, P < 0.001). Greater weight loss resulted in higher cumulative normalization rates of GGT and ALT. Weight loss (OR = 1.21, 95% CI 1.11-1.32, P < 0.001), ALT normalization (OR = 2.75, 95% CI 1.41-5.36, P = 0.01) and lower TG and HOMA-IR values (OR = 2.03, 95% CI 1.11-3.71, P = 0.02; OR = 2.04, 95% CI 1.07-3.89, P = 0.03) were independent protective factors for GGT normalization. Elevated baseline GGT (OR = 0.99, 95% CI 0.98-0.99, P = 0.01) was a risk factor. Conclusions For NAFLD patients with concurrently increased ALT and GGT levels, a lower normalization rate of GGT was observed, rather than ALT. Good control of weight and insulin resistance was a reliable predictor of GGT normalization.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Normalization of γ-glutamyl transferase levels is associated with better metabolic control in individuals with nonalcoholic fatty liver disease
    Qianqian Ma
    Xianhua Liao
    Congxiang Shao
    Yansong Lin
    Tingfeng Wu
    Yanhong Sun
    Shi-Ting Feng
    Junzhao Ye
    Bihui Zhong
    [J]. BMC Gastroenterology, 21
  • [2] γ-Glutamyl transferase: a marker of nonalcoholic fatty liver disease in patients with the metabolic syndrome
    Zaineff Banderas, Diana
    Escobedo, Jorge
    Gonzalez, Evangelina
    Gabriela Liceaga, Maria
    Cenobio Ramirez, Jesus
    Guadalupe Castro, Maria
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2012, 24 (07) : 805 - 810
  • [3] METABOLIC DYSFUNCTION ASSOCIATED FATTY LIVER DISEASE IDENTIFIES SUBJECTS WITH CARDIOVASCULAR RISK BETTER THAN NONALCOHOLIC FATTY LIVER DISEASE
    Chun, Ho Soo
    Lee, Jae Seung
    Lee, Hye Won
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Lee, Yong-Ho
    Kim, Ji-Hye
    Lee, Minjong
    Kim, Seung Up
    [J]. HEPATOLOGY, 2022, 76 : S789 - S789
  • [4] Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome
    Sinn, Dong Hyun
    Kang, Danbee
    Choi, Sung Chul
    Hong, Yun Soo
    Zhao, Di
    Guallar, Eliseo
    Park, Yewan
    Cho, Juhee
    Gwak, Geum-Youn
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (07) : 1873 - +
  • [5] Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease
    Tanaka, Marenao
    Mori, Kazuma
    Takahashi, Satoko
    Higashiura, Yukimura
    Ohnishi, Hirofumi
    Hanawa, Nagisa
    Furuhashi, Masato
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (03) : 700 - 711
  • [6] Identification of metabolic biomarkers associated with nonalcoholic fatty liver disease
    Hua Jiang
    Yang Hu
    Zhibo Zhang
    Xujia Chen
    Jianpeng Gao
    [J]. Lipids in Health and Disease, 22
  • [7] Identification of metabolic biomarkers associated with nonalcoholic fatty liver disease
    Jiang, Hua
    Hu, Yang
    Zhang, Zhibo
    Chen, Xujia
    Gao, Jianpeng
    [J]. LIPIDS IN HEALTH AND DISEASE, 2023, 22 (01)
  • [8] Letter to the Editor: Nonalcoholic Fatty Liver Disease Without Metabolic-Associated Fatty Liver Disease and Metabolic Syndrome
    Kawada, Tomoyuki
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (09) : 2435 - 2435
  • [9] γ-Glutamyl Transferase Is Associated with Mortality Outcomes Independently of Fatty Liver
    Sung, Ki-Chul
    Ryu, Seungho
    Kim, Bum-Soo
    Cheong, Eun Sun
    Park, Dong-Il
    Kim, Byung Ik
    Kwon, Min-Jung
    Wild, Sarah H.
    Byrne, Christopher D.
    [J]. CLINICAL CHEMISTRY, 2015, 61 (09) : 1173 - 1181
  • [10] Metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease: Which can better identify the populations with a high risk of cardiovascular disease?
    Yoshio, Sachiyo
    [J]. HEPATOLOGY RESEARCH, 2021, 51 (11) : 1097 - 1099